Tag Archives: conference

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Posted: March 1, 2024 at 2:45 am

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time

Original post:
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Posted in Global News Feed | Comments Off on Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

Posted: March 1, 2024 at 2:45 am

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 44th Annual Health Care Conference.

Continue reading here:
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

Posted in Global News Feed | Comments Off on Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Posted: January 14, 2024 at 2:35 am

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:00 p.m. EST.

Go here to read the rest:
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Posted in Global News Feed | Comments Off on Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Posted: January 14, 2024 at 2:35 am

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:30 p.m. EST.

Link:
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Posted in Global News Feed | Comments Off on Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…

Posted: January 6, 2024 at 2:37 am

JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.

Originally posted here:
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,...

Posted in Global News Feed | Comments Off on SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,…

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Posted: January 6, 2024 at 2:37 am

LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that it will be presenting at Biotech Showcase in San Francisco, January 8-10 2024. The OKYO management team will also be participating in one-on-one partnering meetings throughout the conference.

Read more:
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

Posted in Global News Feed | Comments Off on OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Posted: January 6, 2024 at 2:37 am

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT.

Read the original:
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Posted in Global News Feed | Comments Off on ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)